Phase II trial of 13-cis-retinoic acid for poor risk HIV-associated Kaposi's sarcoma

International Journal of STD and AIDS

Volumn 8, Issue 8, 1997, Pages 518-521

  Bower, M ^a,b   Fife, K ^a,b   Landau, D ^a   Gracie, F ^a   Phillips, R H ^a   Gazzard, B G ^a  

^a CHELSEA AND WESTMINSTER HOSPITAL   (United Kingdom)

^b CHARING CROSS HOSPITAL   (United Kingdom)

Author keywords

HIV; Kaposi's sarcoma; Retinoids

Indexed keywords

RETINOIC ACID;

ADULT; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG RESPONSE; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; KAPOSI SARCOMA; MALE; ORAL DRUG ADMINISTRATION; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL;

ADULT; AIDS-RELATED OPPORTUNISTIC INFECTIONS; ANTINEOPLASTIC AGENTS; HUMANS; ISOTRETINOIN; MALE; MIDDLE AGED; RISK FACTORS; SARCOMA, KAPOSI;

EID: 0030753068     PISSN: 09564624     EISSN: None     Source Type: Journal    
DOI: 10.1258/0956462971920686     Document Type: Article

References (18)

1. Krown S, Metroka C, Wernz. J. Kaposi's sarcoma in the acquired immune deficiency syndrome: a proposal for uniform evaluation, response, and staging. J Clin Oncol 1989;7:1201 -7
2. Francis GE, Cunningham JM. Growth and differentiation control. In: Pinedo HM, Longo DL, Chabner BA, eds. Cancer Chemotherapy and Biological Response Modifiers, Annual 12. Amsterdam: Elsevier Publications, 1991
3. Cai J, Masood R, Lin G, et al. Retinoic acids inhibit AIDS Kaposi's sarcoma tumour cell growth in vitro and in vivo. Blood 1992;80(suppl 1):327A
4. Corbeil J, Richman DD, Wrasidlo W, Nicolaou KC, Looney DJ. Antiproliferative effects of enediynes on AIDS-derived Kaposi's sarcoma cells. Cancer Res 1994;54:4270-3
5. Guo WX, Gill PS, Antakly T. Inhibition of AIDS-Kaposi's sarcoma cell proliferation following retinoic acid receptor activation. Cancer Res 1995;55:823-9
6. Sidell N, Taga T, Hirano T, Kishimoto T, Saxon A. Retinoic acid-induced growth inhibition of a human myeloma cell line via down-regulation of IL-6 receptors. J Immunol 1991;146:3809-14
7. Huang ME, Ye YC, Chen SR, et al. Use of all-trans-retinoic acid in the treatment of acute promyelocytic leukaemia. Blood 1988;72:567-72
8. Hong WK, Lippman SM, Itri MM, et al. Prevention of second primary tumours with isotretinoin in squamous-cell carcinoma of the head and neck. N Engl J Med 1990;323:795-801
9. Lotan R. Retinoic acid receptors and retinoid-regulated differentiation markers as intermediate endpoints in chemoprevention. Proc Am Assoc Cancer Res 1994;35:684
10. Bonhomme L, Fredj G, Averous S, et al. Topical and systemic treatment of Kaposi's sarcoma with all-transretinoic acid. Biomed Pharmacother 1992;46:327
11. Bailey J, Pluda JM, Foli A, et al. Phase I/II study of intermittent all-trans-retinoic acid, alone and in combination with Interferon alfa-2a, in patients with epidemic Kaposi's sarcoma. J Clin Oncol 1995;13:1966-74
12. Gehan EA. The determination of the number of patients required in a preliminary and follow-up trial of a new chemotherapeutic agent. J Chronic Dis 1961;13:346-53
13. World Health Organization. WHO Handbook for Reporting Results of Cancer Treatment. Geneva (Offset Publication No. 48), 1979
14. Uthayakumar S, Bower M, Money-Kyrle J, et al. Randomised cross-over comparison of liposomal daunorubicin versus observation for early Kaposi's sarcoma. AIDS 1996;10:515-19
15. Ziegler JL, Volberding PA, Itri LM. Failure of isotretinoin in Kaposi's sarcoma [letter]. Lancet 1984;2:641
16. Lewi D, Reboredo G, Jauregui Rueda H, et al. Phase II trial of 13-cis-retinoic acid (CRA) in AIDS-related Kaposi's sarcoma (KS). Proc ASCO 1995;14:292
17. Pluda JM, Shay LE, Foli A, et al. Administration of pentosan polysulfate to patients with human immunodeficiency virus-associated Kaposi's sarcoma. J Natl Cancer Inst 1993;85:1585-92
18. Chang Y, Cesarman E, Pessin MS, et al. Identification of herpes virus-like DNA sequences in AIDS-associated Kaposi's sarcoma. Science 1994;266:1865-9